Detail CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer (article of Cancer Science Vol. 106 Iss.10 October 2015 p.1421–1428) Bibliografi Author: Tjhay, Francisca ; Motohara, Takeshi ; Tayama, Shingo ; Narantuya, Dashdemberel ; Fujimoto, Koichi ; Jianying Guo ; Sakaguchi, Isao ; Honda, Ritsuo ; Tashiro, Hironori ; Katabuchi, Hidetaka Topik: Cancer stem cell; CD44; ovarian cancer; peritoneal metastasis; prognosis; JABFUNG-FKIK-FTJ-2022-01 Bahasa: (EN )     Penerbit: Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association     Tahun Terbit: 2015     Jenis: Article - diterbitkan di jurnal ilmiah internasional Fulltext: B1 Publikasi dr FC Thjay.pdf (2.16MB; 1 download) [Informasi yang berkaitan dengan koleksi ini di internet] Abstract Cancer stem cells (CSCs) drive tumor initiation and metastasis in several types of human cancer. However, the contribution of ovarian CSCs to peritoneal metastasis remains unresolved. The cell adhesion molecule CD44 has been identi?ed as a major marker for CSCs in solid tumors, including epithelial ovarian cancer. CD44 exists as a standard form (CD44s) and also as numerous variant isoforms (CD44v) generated by alternative mRNA splicing. Here we show that disseminated ovarian tumors in the pelvic peritoneum contain highly enriched CD44v6-positive cancer cells, which drive tumor metastasis and are responsible for tumor resistance to chemotherapy. Clinically, an increased number of CD44v6-positive cancer cells in primary tumors was associated with a shortened overall survival in stage III–IV ovarian cancer patients. Furthermore, a subpopulation of CD44v6-positive cancer cells manifested the ability to initiate tumor metastasis in the pelvic peritoneum in an in vivo mouse model, suggesting that CD44v6-positive cells show the potential to serve as metastasis-initiating cells. Thus, the peritoneal disseminated metastasis of epithelial ovarian cancer is initiated by the CD44v6-positive subpopulation, and CD44v6 expression is a biomarker for the clinical outcome of advanced ovarian cancer patients. Given that a distinct subpopulation of CD44v6-positive cancer cells plays a critical role in peritoneal metastasis, de?nitive treatment should target this subpopulation of CD44v6-positive cells in epithelial ovarian cancer. Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Lihat Sejarah Pengadaan  Konversi Metadata   Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved